|
On (b)(6) 2024, the patient underwent treatment for a thoracic aneurysm using an aortic device and a gore® viabahn® endoprosthesis with heparin bioactive surface (viabahn® device) in the superior mesenteric artery (sma) via snorkeling technique.It was reported the physician advanced the delivery catheter through some mild calcification to the target treatment site using a 7f cook introducer sheath over a sv-5 guidewire.The deployment line was pulled and became stuck.The physician was able to pull out 4 inches of the deployment line before it became stuck.Reportedly, there was no distal expansion of the endoprosthesis.The physician re-advanced the sheath over the endoprosthesis, and withdrew the delivery catheter through the sheath without any issues.The procedure was completed using another 8 mm x 15 cm viabahn® device.It was reported there was no impact to the patient.
|
|
Cbas® heparin surface incorporates carmeda heparin manufactured from heparin sodium api, which is covalently bound to the device surface and is essentially non-eluting.W.L.Gore & associates, inc.(gore) is submitting this report to comply with 21 c.F.R.Part 803, the medical device reporting regulation.This report is based upon information obtained by gore, which the company may not have been able to fully investigate or verify prior to the date the report was required by the fda.Blank fields present on this report include required fields and fields determined to be not applicable.Blank required fields indicate that the information was not provided, was deemed unavailable or was not applicable.This report does not constitute an admission or a conclusion by fda, gore, or its associates that the device, gore or its associates caused or contributed to the event described in the report.In particular, this report does not constitute a legal admission by anyone that the product described in this report has any defects or has malfunctioned, as defined from a legal standpoint.These words are included in the report and are fixed items for selection created by the fda, to categorize the type of event solely for the purpose of reporting pursuant to part 803.This statement should be included with any information or report disclosed to the public under the freedom of information act.
|